Street Calls of the Week
Investing.com - Barclays initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with an Overweight rating and a price target of $60.00, representing approximately 30% upside potential from current levels. The stock has shown strong momentum, gaining over 41% in the past six months, with the company maintaining a healthy balance sheet featuring more cash than debt.
The investment bank cited encouraging early clinical data for Kymera’s lead asset, KT-621, a STAT6 degrader being developed for Inflammation & Immunology (I&I) indications.
Barclays noted that recent market trends show investors rewarding oral I&I assets that demonstrate meaningful clinical activity, positioning Kymera favorably in this therapeutic space.
The firm highlighted several recent STAT6 degrader partnerships in the industry, including collaborations between Sanofi/Nurix (NX-3911), Gilead/Leo Pharma, and Kaken Pharmaceuticals/Johnson & Johnson (KP-723), which demonstrate strategic interest in this novel therapeutic approach for blockbuster indications.
Barclays expressed optimism about Kymera’s prospects heading into important proof-of-concept data for KT-621 expected in the fourth quarter of 2025, suggesting significant upside potential for the stock if the data proves clinically meaningful.
In other recent news, Kymera Therapeutics reported its Q2 2025 earnings, which revealed a larger-than-expected loss. The company posted an earnings per share (EPS) of -$0.95, missing analysts’ forecast of -$0.83. Additionally, revenue for the quarter was $11.5 million, falling short of the projected $20 million. Despite the earnings miss, RBC Capital initiated coverage on Kymera Therapeutics with an Outperform rating and a price target of $70. The firm expressed confidence in the potential of Kymera’s lead drug, KT-621, citing positive feedback and expected compelling results in upcoming trials. Furthermore, Wolfe Research raised its price target for Kymera to $88, maintaining an Outperform rating. Wolfe’s analysis suggests that the company’s market capitalization implies significant expected sales for KT-621, potentially reaching 10% of Dupixent’s projected revenue by 2031. These developments highlight the mixed outlook for Kymera Therapeutics, combining earnings challenges with optimistic analyst projections for its drug pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.